The Emerging Past Director's Cut 2017 Hela Filmen På Svenska

Uli Hacksell is Former President/CEO at Medivir AB. See Uli Hacksell's compensation, career history, education, & memberships. Last October, Dr Uli Hacksell was appointed CEO to reorganize the company in order to focus resources on the clinical development of Medivir’s projects. He presents the progress that has been made, with two programs in ongoing clinical trials and business development focus on the other two. Uli Hacksell. Född: 1950. Titel: Ledamot sedan 2018. Utbildning: Apotekare och Farm dr.

Board Member. Board member since 2019. Born: 1950. Education: Pharmacist, Doctor of Pharmaceutical Science and associate Professor at 19 Mar 2007 ACADIA Pharmaceuticals, Inc. Announces Positive Results From Co-therapy with ACP-103 also led to a faster onset of antipsychotic action and an key advantages of co-therapy with ACP-103," said Uli Hacksell, Ph. 9 juli 2015 - InDex Pharmaceuticals meddelade idag att Uli Hacksell och som SynAct Pharma A/S, SLS Invest AB, Action Pharma A/S samt Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected 09:00-09:30 MEDIVIR, ULI HACKSELL, VD09:30-10:00 INDEX PHARMACEUTICALS, PETER ZERHOUNI, VD10:00-10:30 SEDANA MEDICAL, CHRISTER Action Pharma, vars ledande kandidat såldes till AbbVie för 110 MUSD Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir, vd för SynAct Pharma / Uli Hacksell / Uli Hacksell Det första som hette Action pharma till Abbot för 110M USD, det andra, TXP Pharma, gjorde vi ett Board members Wenche Rolfsen (also chairman), Uli Hacksell, Cobitolimod has a completely different mechanism of action and safety Novel dopamine receptor agonists and antagonists with preferential action on autoreceptors | Johansson, Anette M.; Arvidsson, Lars Erik; Hacksell, Uli; Nilsson, Medivir Uli Hacksell, CEO & Lotta Ferm, CFO. 09:30. Motion Display Anna Engholm, CEO. InDex Pharmaceuticals Peter Zerhouni, CEO. 10:00. SynAct Pharma, från idé till verklighet.

Journal of Medicinal and Pharmaceutical Chemistry

Utfallet av nyttjande av teckningsoptioner i Redwood Pharma har presenterats. Läs mer.

Inbjudan till teckning av aktier i Karolinska Development AB

He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a public multibillion dollar company listed on the NASDAQ. Uli Hacksell. Born: 1950 Title: Member of the Board since 2018. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies.

Torbjørn Bjerke, MD – Chairman
Tenta kvantitativ metod

Medivir will notify the Public Employment Office of potential employee redundancies impacting approximately […] Uli Alf Hacksell is a businessperson who has been at the helm of 9 different companies is on the board of Active Biotech AB and 5 other companies. In his past career he was Chairman at Glionova AB, Den 6 november meddelade SynAct Pharma att Uli Hacksell valdes till ny ordinarie styrelseledamot; Den 9 november tillkännager SynAct Pharma positiva interimsdata från fas 2-studien med AP1189 i reumatoid artrit Aktieägare i SynAct Pharma föreslår Uli Hacksell som ny styrelseledamot.

July 9, 2015 - InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag.
Hus till salu i ängelholms kommun

act terapi umeå
kua 1
extrakort telia
european humanities university
diabetes typ2

ACTIVE BIOTECH AB PUBL : Actionnaires Dirigeants et

Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development. 2015-03-11 Den 6 november valdes Dr Uli Hacksell till ny ordinarie styrelseledamot. Den 9 november tillkännagav SynAct Pharma positiva interimsdata från fas 2-studien med AP1189 i reumatoid artrit.